C
Amneal Pharmaceuticals, Inc. AMRX
$10.00 -$0.43-4.12% NASDAQ
Recommendation
Prev Close
$10.43
Volume
9
Avg Vol (90D)
1,577,435
Market Cap
$3.28B
Dividend & Yield
--
52-Week Range
$6.69 - $10.68
P/E (TTM)
1,241.67
EPS (TTM)
$0.01
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
3 Lesser-Known Healthcare Names With Major Upside in Store
10/2/2025 - MarketBeat
Amneal Pharmaceuticals price target raised by $2 at Piper Sandler, here's why
10/31/2025 - The Fly
Amneal Pharmaceuticals (AMRX, $10) Moving Average Convergence Divergence (MACD) Histogram turned negative on October 30, 2025
10/31/2025 - Tickeron - Stocks
How Amneal Pharmaceuticals' (AMRX) Return to Profitability and Respiratory Product Wins Have Changed Its Investment Story
10/30/2025 - Simply Wall St
Amneal Pharmaceuticals Inc (AMRX) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ...
10/30/2025 - GuruFocus
Q3 2025 Amneal Pharmaceuticals Inc Earnings Call Transcript
10/30/2025 - GuruFocus
Amneal Pharmaceuticals, Inc. (AMRX) Q3 2025 Earnings Call Transcript
10/30/2025 - Seeking Alpha: Transcripts
Amneal Pharmaceuticals, Inc. (AMRX) Q3 2025 Earnings Call Transcript
10/30/2025 - SeekingAlpha
Amneal (AMRX) Reports Q3 Earnings: What Key Metrics Have to Say
10/30/2025 - Zacks Investment Research
Amneal Pharmaceuticals (AMRX) Beats Q3 Earnings and Revenue Estimates
10/30/2025 - Zacks Investment Research
Amneal Pharmaceuticals Q3 2025 Earnings: Revenue Surpasses Estimates at $785M, EPS Falls Short ...
10/30/2025 - GuruFocus
Amneal (NASDAQ:AMRX) Beats Q3 Sales Expectations, Stock Soars
10/30/2025 - StockStory Articles
Amneal Pharmaceuticals raises 2025 adjusted EPS view to 75c-80c from 70c-75c
10/30/2025 - The Fly
Amneal Pharmaceuticals reports Q3 adjusted EPS 17c, consensus 14c
10/30/2025 - The Fly
Amneal Reports Third Quarter 2025 Financial Results
10/30/2025 - Globe Newswire
Amneal Pharmaceuticals (AMRX) Receives Tentative FDA Approval for Generic Inhaler
10/29/2025 - GuruFocus
Amneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol
10/29/2025 - Globe Newswire
What To Expect From Amneal Pharmaceuticals Inc (AMRX) Q3 2025 Earnings
10/29/2025 - GuruFocus
Amneal Earnings: What To Look For From AMRX
10/29/2025 - StockStory Articles
Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top Estimates
10/28/2025 - Zacks Investment Research
BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: Should You Buy?
10/27/2025 - Zacks Investment Research
Amneal Pharmaceuticals (AMRX) Launches Brekiya Autoinjector for Migraine and Cluster Headaches
10/27/2025 - GuruFocus
Amneal Pharmaceuticals announces U.S. commercial launch of Brekiya injection
10/27/2025 - The Fly
Amneal Launches Brekiya the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches
10/27/2025 - Globe Newswire
3 Cash-Producing Stocks with Questionable Fundamentals
10/27/2025 - StockStory Articles
Income Statement
Total Revenue (TTM)
$2.85B
EBITDA (TTM)
$625.08M
EBIT (TTM)
$379.72M
Net Income (TTM)
$3.38M
Balance Sheet
Total Assets (Q)
$3.42B
Total Debt (Q)
$2.58B
Total Liabilities (Q)
$3.47B
Book Value Per Share (Q)
-$0.357
Cash Flow
Cash from Operations (TTM)
$351.08M
Cash from Investing (TTM)
-$81.12M
Cash from Financing (TTM)
-$234.40M
Net Change in Cash (TTM)
$34.05M
Filings
Filing Date
Thursday, August 7, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Nov 10 and 14 (est)
Price History
Loading...
Beta
1.35
7-Day Total Return
-2.82%
30-Day Total Return
1.94%
60-Day Total Return
24.22%
90-Day Total Return
23.00%
Year to Date Total Return
28.87%
1-Year Total Return
16.69%
2-Year Total Return
157.73%
3-Year Total Return
354.55%
5-Year Total Return
140.38%
52-week Low
Apr 10, 2025 - $6.69
52-week High
Oct 03, 2025 - $10.68
Valuation
Market Cap
$3.28B - Mid Cap
Enterprise Value
$5.85B
Price/Sales (TTM)
1.18
Price/Book (Q)
-29.22
Dividends and Shares
Shares Outstanding
322.36
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.amneal.com
Phone Number
908 947 3120
Address
400 Crossing Boulevard
Bridgewater, NJ 08807
Country
United States
Year Founded
2002
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical... more
NASDAQ 10/30/2025 4:00PM Eastern Quotes delayed